** Shares of biopharmaceutical firm Medpace Holdings Inc MEDP.O rise 20.1% to $224.85 in
extended trading
** MEDP posts Q1 profit of $2.27/shr, above analysts' estimates Of $1.80/shr - Refinitiv
data
** Co's Q1 revenue of $434.1 mln, also ahead of estimates of $401.8 mln
** Sees 2023 revenue in range of $1.745 bln to $1.805 bln; 2023 EPS in range of $7.81 to
$8.40
** Including session's gains, stock has fallen 11.84%~ YTD
(Reporting by Sruthi Narasimha Chari in Bengaluru)
((Sruthinarasimha.chari@thomsonreuters.com))